CMS Finalizes NGS Test National Coverage Determination, Removes Evidence Development for LDTs

Mar 16, 2018

This article has been updated with information about NGS cancer panels with FDA-approved companion diagnostic indications.

NEW YORK (GenomeWeb) – CMS on Friday finalized the draft national coverage determination it issued last year on next-generation sequencing cancer panels, altering the determination to no longer include coverage with evidence development (CED) for tests that haven't been approved by the US Food and Drug Administration.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Featured White Papers

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Apr

26

Featured Webinar

Evaluation of a Pan-Cancer Cell-Free Assay to Meet Unmet Research Needs

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

May

01

Featured Webinar

Analytical Validation of a Liquid Biopsy Assay for High-Sensitivity Molecular Profiling

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May

08

Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

May

22

Featured Webinar

From Qualitative to Quantitative: Experiences with a cfDNA Assay in Metastatic Breast Cancer Research

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.

Main menu